This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 10.71% and 196.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 6.67% and 65.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Revance Therapeutics (RVNC) delivered earnings and revenue surprises of 25% and 1.10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Krystal Biotech (KRYS) delivered earnings and revenue surprises of 72% and 18.66%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of -3.92% and 16.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
by Zacks Equity Research
QIAGEN's (QGEN) NGS interpretation software, QCI Interpret, now covers the whole exome due to additional AI capabilities.
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 41.67% and 8.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Mirati (MRTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Mirati (MRTX) delivered earnings and revenue surprises of 5.88% and 1.63%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?